Charles Newton
Director of Finance/CFO at LYELL IMMUNOPHARMA, INC.
Net worth: 119 883 $ as of 2024-05-30
Charles Newton active positions
| Companies | Position | Start | End |
|---|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Director of Finance/CFO | 2021-01-31 | - |
| COHERUS BIOSCIENCES, INC. | Director/Board Member | 2022-05-04 | - |
| Independent Dir/Board Member | 2022-05-04 | - | |
| 2SEVENTY BIO, INC. | Director/Board Member | 2024-03-19 | - |
| Independent Dir/Board Member | 2024-03-19 | - |
Career history of Charles Newton
Former positions of Charles Newton
| Companies | Position | Start | End |
|---|---|---|---|
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Director/Board Member | 2023-07-18 | 2023-12-31 |
| Independent Dir/Board Member | 2023-07-18 | 2023-12-31 | |
Credit Suisse Group AG /US/
 Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Chief Executive Officer | 2010-08-31 | 2015-10-31 |
| MORGAN STANLEY | Corporate Officer/Principal | 1996-05-31 | 2010-08-31 |
BofA Securities, Inc.
 BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Corporate Officer/Principal | - | - |
Training of Charles Newton
| Tuck School of Business at Dartmouth | Masters Business Admin |
| Miami University | Undergraduate Degree |
Statistics
International
| United States | 10 |
Operational
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
| Corporate Officer/Principal | 2 |
Sectoral
| Health Technology | 5 |
| Finance | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 4 |
|---|---|
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| COHERUS BIOSCIENCES, INC. | Health Technology |
| MORGAN STANLEY | Finance |
| 2SEVENTY BIO, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Credit Suisse Group AG /US/
Credit Suisse Group AG /US/ Financial ConglomeratesFinance Credit Suisse Group AG /US/ engages in the provision of financial solutions. It offers services for private banking, investment banking, and asset management. The company is headquartered in New York, NY. | Finance |
BofA Securities, Inc.
BofA Securities, Inc. Investment Banks/BrokersFinance BofA Securities, Inc. is a registered broker-dealer subsidiary of NB Holdings Corp., ultimately held by Bank of America Corp. (NYSE: BAC). Headquartered in New York, the firm was founded in 2015 and offers trade execution, trading or brokerage services to institutional clients. | Finance |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Stock Market
- Insiders
- Charles Newton
- Experience
